- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ad Stars: BBDO (Cypher)
DEVICE DTC
agency: BBDO
brand: Cypher
client: Cordis, a Johnson & Johnson company Agency team names withheld at client's request
A drug-eluding stent isn't something that's typically considered "patient's choice," so it seems counterintuitive to create consumer print ads to promote them. But to the surprise of industry watchers, that's just what BBDO did. Check out the agency's eye-catching campaign for Johnson & Johnson's Cypher stent, launched as full-page spreads in magazines and newspapers beginning in October 2007.
The spots feature people engaging in everyday physical activities, from jogging to playing with children. They also show the actual size of a stent and offer risk-and-benefit information. We like these ads because they educate consumers in an area where most say they don't need to be educated—and that's just nonsense. "It's up to the doctor to determine what's best for the patient, but we wanted to make sure the information was out there," said Cordis' Carol Goodrich, director of corporate communications. "It really is all about physician and patient interaction and conversation about coronary-artery disease."
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
